To the best of our knowledge, only two clinical trials using targeted therapy against IGF-IR are currently ongoing in ovarian cancer patients (clinicaltrials.gov identifier: NCT00719212 and NCT00718523). This evidence concerns the gene IGF1R and ovarian cancer.